Selnoflast clinical trials
Also written RO7486967.
Includes 1 study of Selnoflast potassium.
How each study uses selnoflast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the selnoflast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Hoffmann-La Roche (1) · Inflazome UK Ltd (1) · Genentech, Inc. (1)
Studies
Open first, then newest update. How each study uses selnoflast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac EventsRecruitingPhase 2Genentech, Inc.NCT07448038Written as Selnoflast
- A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.CompletedPhase 1Hoffmann-La RocheNCT05924243Written as RO7486967
- Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334CompletedPhase 1Inflazome UK LtdNCT04086602Written as IZD334
Codes
What other systems call selnoflast · ClinicalTrials.gg INT017959
- UNII (FDA) T23RPA8WA2SELNOFLASTOne source FDA
- NCI Thesaurus C184882SelnoflastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T23RPA8WA2 | SELNOFLAST | One source FDA |
| NCI Thesaurus | C184882 | Selnoflast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.